Karim Lalji

Mr. Lalji began his career with Merck & Company. While at Merck, he led the infectious disease new product portfolio from the commercial perspective, with responsibility for products such as INVANZ, CANCIDAS and CRIXIVAN, and he also drove the global franchise strategies for cholesterol reducers and hypertension/heart failure treatments. His final role during his ten-year tenure at Merck was as an executive leading the worldwide osteoporosis franchise and its main product, FOSAMAX.

Subsequent to Merck, Mr. Lalji worked at Sepracor, Inc., where he was VP of Business Strategy and New Product Commercialization. He was the primary architect of LUNESTA for the treatment of insomnia. In 2006, Mr. Lalji joined Cardiome Pharma Corp. as Senior VP of Commercial Affairs and an officer of the company. He played a pivotal role in driving Cardiome's US $800 million global development and co-commercialization licensing deal with Merck & Company for vernakalant oral and IV for the management of atrial fibrillation.

Mr. Lalji serves on the Board of Overseers of Harvard University's Beth Israel Deaconess Medical Center in Boston. He holds a Science Masters Degree in Health Policy and Management from Harvard University, and a BBA from Simon Fraser University in British Columbia.